197 related articles for article (PubMed ID: 24442204)
1. GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target.
Herath NI; Rocques N; Garancher A; Eychène A; Pouponnot C
Blood Cancer J; 2014 Jan; 4(1):e175. PubMed ID: 24442204
[TBL] [Abstract][Full Text] [Related]
2. Identification of primary MAFB target genes in multiple myeloma.
van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.
Annunziata CM; Hernandez L; Davis RE; Zingone A; Lamy L; Lam LT; Hurt EM; Shaffer AL; Kuehl WM; Staudt LM
Blood; 2011 Feb; 117(8):2396-404. PubMed ID: 21163924
[TBL] [Abstract][Full Text] [Related]
4. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
Suzuki A; Iida S; Kato-Uranishi M; Tajima E; Zhan F; Hanamura I; Huang Y; Ogura T; Takahashi S; Ueda R; Barlogie B; Shaughnessy J; Esumi H
Oncogene; 2005 Oct; 24(46):6936-44. PubMed ID: 16044163
[TBL] [Abstract][Full Text] [Related]
5. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract][Full Text] [Related]
6. Exploring Large MAF Transcription Factors: Functions, Pathology, and Mouse Models with Point Mutations.
Fujino M; Ojima M; Takahashi S
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895232
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
8. Neither MafA/L-Maf nor MafB is essential for lens development in mice.
Takeuchi T; Kudo T; Ogata K; Hamada M; Nakamura M; Kito K; Abe Y; Ueda N; Yamamoto M; Engel JD; Takahashi S
Genes Cells; 2009 Aug; 14(8):941-7. PubMed ID: 19624757
[TBL] [Abstract][Full Text] [Related]
9. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
10. A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells.
Nishimura W; Kondo T; Salameh T; El Khattabi I; Dodge R; Bonner-Weir S; Sharma A
Dev Biol; 2006 May; 293(2):526-39. PubMed ID: 16580660
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
He Y; Wang S; Tong J; Jiang S; Yang Y; Zhang Z; Xu Y; Zeng Y; Cao B; Moran MF; Mao X
J Biol Chem; 2020 Feb; 295(7):2084-2096. PubMed ID: 31822558
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis.
Wang S; Juan J; Zhang Z; Du Y; Xu Y; Tong J; Cao B; Moran MF; Zeng Y; Mao X
Cell Death Dis; 2017 Sep; 8(9):e3058. PubMed ID: 28933784
[TBL] [Abstract][Full Text] [Related]
13. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity.
Asano K; Kikuchi K; Takehara M; Ogasawara M; Yoshioka Y; Ohnishi K; Iwata A; Shimizu S; Tanaka M
Biochem Biophys Res Commun; 2023 Dec; 684():149135. PubMed ID: 37879249
[TBL] [Abstract][Full Text] [Related]
14. Role of large MAF transcription factors in the mouse endocrine pancreas.
Abdellatif AM; Ogata K; Kudo T; Xiafukaiti G; Chang YH; Katoh MC; El-Morsy SE; Oishi H; Takahashi S
Exp Anim; 2015; 64(3):305-12. PubMed ID: 25912440
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of pancreatic endocrine progenitors reversibly blocked by premature induction of MafA.
He KH; Juhl K; Karadimos M; El Khattabi I; Fitzpatrick C; Bonner-Weir S; Sharma A
Dev Biol; 2014 Jan; 385(1):2-12. PubMed ID: 24183936
[TBL] [Abstract][Full Text] [Related]
16. SUMOylation negatively regulates transcriptional and oncogenic activities of MafA.
Kanai K; Reza HM; Kamitani A; Hamazaki Y; Han SI; Yasuda K; Kataoka K
Genes Cells; 2010 Sep; 15(9):971-82. PubMed ID: 20718938
[TBL] [Abstract][Full Text] [Related]
17. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
18. Cell context reveals a dual role for Maf in oncogenesis.
Pouponnot C; Sii-Felice K; Hmitou I; Rocques N; Lecoin L; Druillennec S; Felder-Schmittbuhl MP; Eychène A
Oncogene; 2006 Mar; 25(9):1299-310. PubMed ID: 16247450
[TBL] [Abstract][Full Text] [Related]
19. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
[TBL] [Abstract][Full Text] [Related]
20. The protozoan parasite Theileria annulata alters the differentiation state of the infected macrophage and suppresses musculoaponeurotic fibrosarcoma oncogene (MAF) transcription factors.
Jensen K; Makins GD; Kaliszewska A; Hulme MJ; Paxton E; Glass EJ
Int J Parasitol; 2009 Aug; 39(10):1099-108. PubMed ID: 19303416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
